PCM
ABUS icon

Prelude Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Prelude Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-45,300
Closed -$161K – 1505
2020
Q4 		$161K Buy
45,300
+300
+0.7% +$1.05K ﹤0.01% 1144
2020
Q3 		$141K Buy
+45,000
New +$137K 0.01% 792

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Prelude Capital Management's ABUS Position: Q1 2026 in Review

Prelude Capital Management held its Arbutus Biopharma (ABUS) position steady in Q1 2026 at 25,318 shares worth $114K. The position accounts for 0.01% of the portfolio, ranked #1030.

Prelude Capital Management first reported a position in ABUS in Q4 2014 and has held it in 17 quarters since. The position peaked at $186K in Q2 2022. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Prelude Capital Management held 25,318 shares of Arbutus Biopharma worth $114K as of Q1 2026.
  • Prelude Capital Management left its Arbutus Biopharma share count unchanged in Q1 2026.
  • Arbutus Biopharma made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1030 holding.
  • Prelude Capital Management first reported a position in Arbutus Biopharma in Q4 2014 and has held it in 17 quarters since.
  • Prelude Capital Management's Arbutus Biopharma position peaked at $186K in Q2 2022.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.